Recombinant influenza vaccines.

All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines. J Virol (2014) 0.81

Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine (2015) 0.76

Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? Mol Cell Ther (2013) 0.75

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection. Biomed Res Int (2017) 0.75

Artificially designed pathogens - a diagnostic option for future military deployments. Mil Med Res (2015) 0.75

Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19

1918 Influenza: the mother of all pandemics. Emerg Infect Dis (2006) 12.11

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13

The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. J Virol (2006) 3.03

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol (2007) 2.82

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76

Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol (1997) 2.75

Recombinant Newcastle disease virus as a vaccine vector. J Virol (2001) 2.67

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine (2007) 2.31

Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol (2006) 2.08

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol (2001) 2.04

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther (2004) 2.04

Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol (2010) 1.96

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine (2005) 1.79

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67

Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66

Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet (1994) 1.62

Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61

Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers. J Clin Microbiol (1986) 1.52

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine (2011) 1.51

A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol (2007) 1.50

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine (2008) 1.48

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol (1992) 1.38

DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34

Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev (2005) 1.33

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines (2010) 1.31

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30

Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine (1996) 1.29

A review of vaccine research and development: human acute respiratory infections. Vaccine (2005) 1.27

Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine (2008) 1.21

Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol (2007) 1.20

Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol (2005) 1.19

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis (2010) 1.18

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol (2010) 1.17

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine (2010) 1.17

Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS (2010) 1.14

Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks. Virology (2006) 1.10

Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One (2009) 1.08

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine (2008) 1.05

Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One (2011) 1.03

Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One (2012) 1.02

Eukaryotic expression plasmid transfer from the intracellular bacterium Listeria monocytogenes to host cells. Cell Microbiol (2001) 1.02

Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01

Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccine (1997) 1.00

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One (2012) 1.00

Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother (2012) 1.00

Influenza virus infection of a newborn rats: virulence of recombinant strains prepared from a cold-adapted, attenuated parent. Arch Virol (1979) 0.96

Assessment of Lactobacillus gasseri as a candidate oral vaccine vector. Clin Vaccine Immunol (2011) 0.94

Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol (2005) 0.93

Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med (Berl) (2010) 0.93

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One (2011) 0.92

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol (2010) 0.91

Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol (2011) 0.91

Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expr Purif (2007) 0.89

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc) (2012) 0.88

Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol (2009) 0.88

Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine (2010) 0.87

Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol Immunol (2011) 0.87

Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine (2001) 0.84

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respir Res (2011) 0.83

Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine (2009) 0.83

The cleavage of the hemagglutinin protein of H5N2 avian influenza virus in yeast. J Virol Methods (2007) 0.83

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology (2012) 0.83

Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. Vaccine (2009) 0.82

Targets for the induction of protective immunity against influenza a viruses. Viruses (2010) 0.82

Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases. Expert Rev Vaccines (2011) 0.81

Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol (2011) 0.80

Platycodin d improves the immunogenicity of newcastle disease virus-based recombinant avian influenza vaccine in mice. Chem Biodivers (2010) 0.80

In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB). Vaccine (2009) 0.80

Recommendations from the avian influenza vaccine workshop. Ann N Y Acad Sci (2006) 0.80

Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine (2011) 0.78

Behavior of Transplanted Multipotent Cells after in Vitro Transplantation into the Damaged Retina. Acta Naturae (2011) 0.77

[Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors]. Zh Mikrobiol Epidemiol Immunobiol (2010) 0.77

[Avian influenza vaccines]. Vopr Virusol (2009) 0.76

[Development of the anti-influenza H5N1 vaccines worldwide and in Russia]. Zh Mikrobiol Epidemiol Immunobiol (2006) 0.76

[Universal influenza vaccines: developments, prospects for use]. Vopr Virusol (2012) 0.76

[Vaccines and chemicals for the prevention of influenza]. Vopr Virusol (2007) 0.76

[The role of pattern-recognizing receptors in anti-infectious immunity]. Vestn Ross Akad Med Nauk (2011) 0.76

Evaluation of the immune response to recombinant DNA vaccine and adenoviral vaccine co-expressing the M1 and HA genes of H5N1 influenza virus in mice. Sheng Wu Gong Cheng Xue Bao (2011) 0.76

Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro. Acta Naturae (2011) 0.76

Development of a diagnostic test for Yersinia pestis by the polymerase chain reaction. J Appl Bacteriol (1994) 1.28

Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene (2008) 1.20

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol (2005) 1.11

DNA-polycation complexes: effect of polycation structure on physico-chemical and biological properties. J Biotechnol (2006) 0.94

Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta Naturae (2010) 0.91

Non-thermal Plasma Causes p53-Dependent Apoptosis in Human Colon Carcinoma Cells. Acta Naturae (2012) 0.89

Amyloidogenic peptide homologous to beta-domain region of alpha-lactalbumin. Dokl Biochem Biophys (2007) 0.89

Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 Virus. Acta Naturae (2010) 0.88

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc) (2012) 0.88

[Influence of environmental factors on the expression of Mycoplasma pneumoniae gene responsible for the synthesis of protein P1 adhesion]. Zh Mikrobiol Epidemiol Immunobiol (2003) 0.86

Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther (2004) 0.86

[Evolution of avian influenza viruses H5N1 (1997-2004) in southern and south-eastern Asia]. Vopr Virusol (2005) 0.85

[Biofilms as a mode of existence of bacteria in external environment and host body: the phenomenon, genetic control, and regulation systems of development]. Genetika (2004) 0.85

[Genetic control of the induction of a nonculturable state in pathogenic bacteria]. Zh Mikrobiol Epidemiol Immunobiol (1996) 0.85

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84

[Analysis of pandemic influenza in Russia as a part of the global process based on data of an influenza monitoring reference center]. Zh Mikrobiol Epidemiol Immunobiol (2011) 0.83

Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection. Acta Naturae (2012) 0.82

[Analysis of the plasmid composition of Yersinia pseudotuberculosis strains and its use for typing pseudotuberculosis pathogens]. Mol Gen Mikrobiol Virusol (1989) 0.82

[A common antigenic epitope in influenza A virus (H1, H2, H5, H6) hemagglutinin]. Vopr Virusol (1999) 0.82

Amplification of DNA sequences of Epstein-Barr and human immunodeficiency viruses using DNA-polymerase from Thermus thermophilus. Mol Cell Probes (1990) 0.82

[The 2009 pandemic influenza in Russia. I. Diagnosis and molecular biological characteristics of the virus]. Vopr Virusol (2011) 0.81

Atomic force microscopy study of peptides homologous to beta-domain of alpha-lactalbumins. Protein Pept Lett (2007) 0.81

Prevalence of genes encoding exfoliative toxins among Staphylococcus hyicus isolated in Russia and Germany. J Vet Med B Infect Dis Vet Public Health (2006) 0.81

[Cowpea mosaic virus chimeric particles bearing ectodomain of matrix protein 2 (M2E) of influenza A virus: production and characteristics]. Mol Biol (Mosk) (2009) 0.81

[Detection of the genes of pyrogenic toxins of superantigens in clinical isolates of methicillin resistant Staphylococcus aureus]. Zh Mikrobiol Epidemiol Immunobiol (2006) 0.81

[Prospects for the use of low-temperature gas plasma as an antimicrobial agent]. Vestn Ross Akad Med Nauk (2011) 0.81

[Antiviral activity of several vasodilator agents]. Biull Eksp Biol Med (1996) 0.81

DNA sequencing with thermostable Tet DNA polymerase from Thermus thermophilus. Nucleic Acids Res (1989) 0.80

[Eukaryotic vectors of Celo avian adenovirus genome, carrying GFP and human IL-2 genes]. Mol Gen Mikrobiol Virusol (2002) 0.80

[Target-directed search of anti-virulence drugs]. Zh Mikrobiol Epidemiol Immunobiol (2009) 0.80

[The possibility of preserving the causative agent of plague in soil in resting (nonculturable) form]. Zh Mikrobiol Epidemiol Immunobiol (1997) 0.80

[Secondary structure of the M2 protein of influenza type A virus and its role in forming resistance to rimantadine and deitiforin]. Mol Biol (Mosk) (1995) 0.79

The efficacy of cell therapy in the treatment of patients with trophic venous ulcers of the lower limbs. Angiol Sosud Khir (2007) 0.79

Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res (1999) 0.79

[Type III bacterial secretion system, a promising target for the development of a new generation of antibiotic drugs]. Vestn Ross Akad Med Nauk (2008) 0.79

[Comparative evaluation of the efficacy of Borrelia indication in ixodes ticks (Ixodidae) using dark field microscopy and polymerase chain reaction (PCR)]. Parazitologiia (2001) 0.79

[Molecular characteristic of influenza virus A H5N1 Strains isolated from poultry in Kurgan Region in 2005]. Mol Biol (Mosk) (2008) 0.78

[Analysis of the nucleotide sequence of a fragment (92-100%) of the CELO avian adenovirus genome]. Mol Gen Mikrobiol Virusol (1993) 0.78

[Universal diagnostic oligonucleotide microarray for subtyping of human and animal influenza A viruses]. Vopr Virusol (2014) 0.78

Adenoviral transduction of multipotent mesenchymal stromal cells from human adipose tissue with bone morphogenetic protein BMP-2 gene. Bull Exp Biol Med (2013) 0.78

[Electron microscope maps of SA7 DNA melting]. Mol Biol (Mosk) (1985) 0.78

Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo. Virus Res (2004) 0.78

[Activation of free radicals reaction and changes in the state of antioxidant protection in blood in toxic experimental influenza infection]. Biull Eksp Biol Med (1992) 0.78

[Sequence analysis of hexon gene from adenovirus KR95 inducing hydropericardium syndrome in chickens]. Mol Gen Mikrobiol Virusol (2000) 0.78

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB. Acta Naturae (2011) 0.78

[Effector proteins of Clamidia]. Mol Biol (Mosk) (2010) 0.78

An Efficient Method for the Delivery of the Interleukin-2 Gene to Human Hematopoietic Cells using the 
Fiber-Modified Recombinant Adenovirus. Acta Naturae (2011) 0.78

Transcription termination factor rho and T-even phage development. Mol Gen Genet (1980) 0.78

[Structural-functional characteristics of Yersinia pseudotuberculosis plasmid pVM82]. Genetika (1990) 0.77

Fatty acid acylated antibodies against virus suppress its reproduction in cells. FEBS Lett (1989) 0.77

[Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1]. Zh Mikrobiol Epidemiol Immunobiol (2010) 0.77

[Construction of the vector based on the CELO avian adenovirus genome providing enhanced expression of secreted alkaline phosphatase gene in a non-permissive system in vitro and in vivo]. Mol Gen Mikrobiol Virusol (2008) 0.77

[Correlation between activity of the phosphoenol-pyruvate-dependable phosphotransferase system (PTS) and synthesis of adhesion P1 protein in Mycoplasma pneumoniae]. Mol Gen Mikrobiol Virusol (2003) 0.77

[In vitro and in vivo effects of ingavirin on the ultrastructure and infectivity of influenza virus]. Vopr Virusol (2011) 0.77

[Role of apoptosis in the regulation of the infectious process]. Zh Mikrobiol Epidemiol Immunobiol (2005) 0.77

[Experimental study of Ingavirin antiviral activity against human adenovirus]. Antibiot Khimioter (2010) 0.77

[Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors]. Zh Mikrobiol Epidemiol Immunobiol (2010) 0.77

[Formation of biofilms as an example of the social behavior of bacteria]. Mikrobiologiia (2006) 0.77

[Protective activity of Ingavirin in experimental lethal influenza due to pandemic influenza virus A (H1N1)v in albino mice]. Antibiot Khimioter (2010) 0.77

[Lipid-associated membrane lipopeptides of M. arginini activate NF-kB by interacting with TLR2/1, TLR2/6, and TLR2/CD14]. Mol Gen Mikrobiol Virusol (2009) 0.77

[Effect of different water-soluble forms of the fullerene C60 on the metabolic activity and ultra-structure of cells in culture]. Biofizika (2012) 0.77

Toll-like receptors and their adapter molecules. Biochemistry (Mosc) (2010) 0.77

[The induction of protective immune response in mice vaccinated by recombinant avian adenovirus CELO expressing glycoprotein G of the rabies virus]. Zh Mikrobiol Epidemiol Immunobiol (2006) 0.77

Gene therapy of amyotrophic lateral sclerosis. Bull Exp Biol Med (2008) 0.77

[Antiviral activity of Ingavirin in experimental lethal influenza due to influenza virus B in albino mice]. Antibiot Khimioter (2010) 0.77

[Sulfated polysaccharides of brown seaweeds--ligands of toll-like receptors]. Biomed Khim (2012) 0.77

Development of Recombinant Vaccine against A(H1N1) 2009 Influenza Based on Virus-like Nanoparticles Carrying the Extracellular Domain of M2 Protein. Acta Naturae (2010) 0.77

[Universal influenza vaccines: developments, prospects for use]. Vopr Virusol (2012) 0.76

[Production of mycobacterial antigenes merged with cellulose binding protein domain in order to produce subunit vaccines against tuberculosis]. Mol Gen Mikrobiol Virusol (2012) 0.76

[Development of the anti-influenza H5N1 vaccines worldwide and in Russia]. Zh Mikrobiol Epidemiol Immunobiol (2006) 0.76

Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro. Acta Naturae (2011) 0.76

Insulin fibrillogenesis in vitro. Dokl Biochem Biophys (2008) 0.76

[Experimental investigation of Ingavirin antiviral activity against human parainfluenza virus]. Antibiot Khimioter (2010) 0.76

[Reconstruction of autonomic genetic and protein-synthesizing systems from viral RNA and isolated mitochondria]. Dokl Akad Nauk SSSR (1971) 0.76

[Smallpox is a dormant volcano]. Vopr Virusol (2008) 0.76